Article

OctoPlus Opens New GMP Manufacturing Facility

Author(s):

OctoPlus has started production in its new manufacturing facility in Leiden.

Netherlands-based biopharmaceutical company OctoPlus N.V. has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products according to international good manufacturing practice (GMP) guidelines.

OctoPlus began expanding its headquarters in November 2006. The new building comprises offices, laboratories, and a GMP manufacturing plant that produces final drug product for the company’s clients.

With the expansion, OctoPlus has more than doubled its manufacturing capacity and the company can now produce clinical scale Phase 1, 2, and 3 and even small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.